Combination Therapy Bests Standard of Care in BRAF+ CRCJanuary 28th 2020
Encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) demonstrated longer maintenance of quality of life (QoL) on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract CancerJanuary 24th 2019
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer (BTC) who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.
Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast CancerJanuary 5th 2019
Combining the BCL-2 inhibitor venetoclax (Venclexta) with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor (ER)–positive and BCL-2–positive metastatic breast cancer.
Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-upDecember 28th 2018
CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival (DFS) and overall survival (OS) similar to the reference product in the treatment of patients with HER2-positive early breast cancer.
PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBCDecember 19th 2018
Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) in patients with metastatic triple-negative breast cancer (TNBC) or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells, according to a biomarker subgroup analysis of the phase III IMpassion130 study.1
Trifluridine/Tipiracil Improves Survival in Heavily Pretreated Gastric/GEJ CancerNovember 2nd 2018
Trifluridine/tipiracil (FTD/TPI; Lonsurf) reduced the risk of death in patients with heavily pretreated gastric or gastroesophageal junction (GEJ) cancer by 31% compared with placebo, according to data from the phase III TAGS trial.
Standard of Care Reigns Superior for Low-Risk HPV+ Oropharyngeal CancerOctober 29th 2018
Though many patients with HPV-positive oropharyngeal cancer have been treated with cetuximab (Erbitux), results from the international De-ESCALaTE HPV trial showed that chemoradiotherapy, the current standard of care, is still the most effective.
CAR T-Cell Therapy: Nursing's Key Role in Educating Patients, Caregivers About What to ExpectFebruary 27th 2017
When treating patients with CAR T-cell therapy, it is important that nurses are involved in the patient education and care coordination, so patients can be fully prepared for potential adverse events.
Follow-up Confirms Safety of Radium-223 in mCRPCApril 1st 2014
Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.
Longer Bortezomib Duration Linked to Improved Survival in Multiple MyelomaMarch 7th 2014
A higher cumulative dose of the proteasome inhibitor bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve overall survival in patients with previously untreated multiple myeloma